CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ARIH2 (ImmuneEditome ID:10425)

1. Gene summary of enriched editing regions for ARIH2

check button Gene summary
Gene informationGene symbol

ARIH2

Gene ID

10425

GeneSynonymsARI2|TRIAD1
GeneCytomap

3p21.31

GeneTypeprotein-coding
GeneDescriptionE3 ubiquitin-protein ligase ARIH2|RING-type E3 ubiquitin transferase ARIH2|all-trans retinoic acid inducible RING finger|ariadne homolog 2|protein ariadne-2 homolog
GeneModificationdate20230517
UniprotIDO95376;Q6IBL8;C9JBC5;F8WCS4;C9JAU2;C9JZ71;C9JCL4
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr3:48923271-48925364:+ENST00000463204.4ENSG00000177479.18ARIH2ncRNA_exonicAluJr,(ATT)n,FLAM_C,AluSz6,SVA_E,AluSc8,AluSp,(TTTATTT)n,AluYchr3:48923271-48925364:+.alignment
chr3:48923271-48925364:+ENST00000463738.4ENSG00000177479.18ARIH2ncRNA_exonicAluJr,(ATT)n,FLAM_C,AluSz6,SVA_E,AluSc8,AluSp,(TTTATTT)n,AluYchr3:48923271-48925364:+.alignment
chr3:48923271-48925364:+ENST00000474936.5ENSG00000177479.18ARIH2ncRNA_exonicAluJr,(ATT)n,FLAM_C,AluSz6,SVA_E,AluSc8,AluSp,(TTTATTT)n,AluYchr3:48923271-48925364:+.alignment
chr3:48923271-48925364:+ENST00000488963.4ENSG00000177479.18ARIH2ncRNA_exonicAluJr,(ATT)n,FLAM_C,AluSz6,SVA_E,AluSc8,AluSp,(TTTATTT)n,AluYchr3:48923271-48925364:+.alignment
chr3:48923271-48925364:+ENST00000492077.4ENSG00000177479.18ARIH2ncRNA_exonicAluJr,(ATT)n,FLAM_C,AluSz6,SVA_E,AluSc8,AluSp,(TTTATTT)n,AluYchr3:48923271-48925364:+.alignment
chr3:48936429-48936997:+ENST00000463204.4ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluYchr3:48936429-48936997:+.alignment
chr3:48936429-48936997:+ENST00000470296.4ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluYchr3:48936429-48936997:+.alignment
chr3:48936429-48936997:+ENST00000474618.4ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluYchr3:48936429-48936997:+.alignment
chr3:48936429-48936997:+ENST00000474936.5ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluYchr3:48936429-48936997:+.alignment
chr3:48936429-48936997:+ENST00000478224.4ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluYchr3:48936429-48936997:+.alignment
chr3:48936429-48936997:+ENST00000482427.4ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluYchr3:48936429-48936997:+.alignment
chr3:48936429-48936997:+ENST00000483333.4ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluYchr3:48936429-48936997:+.alignment
chr3:48936429-48936997:+ENST00000484999.4ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluYchr3:48936429-48936997:+.alignment
chr3:48936429-48936997:+ENST00000486316.4ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluYchr3:48936429-48936997:+.alignment
chr3:48936429-48936997:+ENST00000488963.4ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluYchr3:48936429-48936997:+.alignment
chr3:48936429-48936997:+ENST00000490095.4ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluYchr3:48936429-48936997:+.alignment
chr3:48936429-48936997:+ENST00000495507.4ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluYchr3:48936429-48936997:+.alignment
chr3:48936429-48936997:+ENST00000495761.4ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluYchr3:48936429-48936997:+.alignment
chr3:48936429-48936997:+ENST00000498314.4ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluYchr3:48936429-48936997:+.alignment
chr3:48938988-48939686:+ENST00000463204.4ENSG00000177479.18ARIH2ncRNA_intronicAluY,AluSx1chr3:48938988-48939686:+.alignment
chr3:48938988-48939686:+ENST00000470296.4ENSG00000177479.18ARIH2ncRNA_intronicAluY,AluSx1chr3:48938988-48939686:+.alignment
chr3:48938988-48939686:+ENST00000474618.4ENSG00000177479.18ARIH2ncRNA_intronicAluY,AluSx1chr3:48938988-48939686:+.alignment
chr3:48938988-48939686:+ENST00000474936.5ENSG00000177479.18ARIH2ncRNA_intronicAluY,AluSx1chr3:48938988-48939686:+.alignment
chr3:48938988-48939686:+ENST00000478224.4ENSG00000177479.18ARIH2ncRNA_intronicAluY,AluSx1chr3:48938988-48939686:+.alignment
chr3:48938988-48939686:+ENST00000482427.4ENSG00000177479.18ARIH2ncRNA_intronicAluY,AluSx1chr3:48938988-48939686:+.alignment
chr3:48938988-48939686:+ENST00000483333.4ENSG00000177479.18ARIH2ncRNA_intronicAluY,AluSx1chr3:48938988-48939686:+.alignment
chr3:48938988-48939686:+ENST00000484999.4ENSG00000177479.18ARIH2ncRNA_intronicAluY,AluSx1chr3:48938988-48939686:+.alignment
chr3:48938988-48939686:+ENST00000486316.4ENSG00000177479.18ARIH2ncRNA_intronicAluY,AluSx1chr3:48938988-48939686:+.alignment
chr3:48938988-48939686:+ENST00000488963.4ENSG00000177479.18ARIH2ncRNA_intronicAluY,AluSx1chr3:48938988-48939686:+.alignment
chr3:48938988-48939686:+ENST00000490095.4ENSG00000177479.18ARIH2ncRNA_intronicAluY,AluSx1chr3:48938988-48939686:+.alignment
chr3:48938988-48939686:+ENST00000495507.4ENSG00000177479.18ARIH2ncRNA_intronicAluY,AluSx1chr3:48938988-48939686:+.alignment
chr3:48938988-48939686:+ENST00000495761.4ENSG00000177479.18ARIH2ncRNA_intronicAluY,AluSx1chr3:48938988-48939686:+.alignment
chr3:48938988-48939686:+ENST00000498314.4ENSG00000177479.18ARIH2ncRNA_intronicAluY,AluSx1chr3:48938988-48939686:+.alignment
chr3:48977102-48978955:+ENST00000490095.4ENSG00000177479.18ARIH2ncRNA_intronicAluSx,AluSx3,AluSx1,(TG)n,AluSc8chr3:48977102-48978955:+.alignment


Top

2. Tumor-specific enriched editing regions for ARIH2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for ARIH2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for ARIH2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for ARIH2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000177479.18,ARIH2BLCAEAGB_cells_naive3.7584e-020.3220image
chr3:48977102-48978955:+BRCAEERB_cells_memory4.8660e-02-0.3829image
ENSG00000177479.18,ARIH2BRCAEAGMacrophages_M22.9115e-02-0.1819image
ENSG00000177479.18,ARIH2CESCEAGB_cells_memory2.1562e-020.4981image
ENSG00000177479.18,ARIH2COADEAGDendritic_cells_activated1.4180e-020.4751image
ENSG00000177479.18,ARIH2ESCAEAGMast_cells_resting4.3616e-020.2182image
ENSG00000177479.18,ARIH2GBMEAGEosinophils2.0513e-020.2937image
ENSG00000177479.18,ARIH2KIRPEAGT_cells_CD4_memory_activated7.3785e-040.6526image
ENSG00000177479.18,ARIH2LAMLEAGMast_cells_activated1.7939e-020.3153image
ENSG00000177479.18,ARIH2LGGEAGEosinophils2.3782e-020.2495image
ENSG00000177479.18,ARIH2LUADEAGEosinophils2.9382e-020.2663image
ENSG00000177479.18,ARIH2LUSCEAGT_cells_follicular_helper2.0818e-02-0.4133image
chr3:48936429-48936997:+OVEERT_cells_gamma_delta2.4826e-020.4232image
chr3:48977102-48978955:+OVEERPlasma_cells4.0500e-020.4301image
ENSG00000177479.18,ARIH2OVEAGNeutrophils2.5900e-02-0.2184image
ENSG00000177479.18,ARIH2PRADEAGMacrophages_M04.5963e-020.3135image
ENSG00000177479.18,ARIH2SARCEAGB_cells_memory3.8215e-020.4550image
chr3:48923271-48925364:+STADEERPlasma_cells3.4812e-030.3311image
chr3:48936429-48936997:+STADEERB_cells_naive9.0354e-030.4233image
chr3:48977102-48978955:+STADEERT_cells_CD4_memory_activated1.9051e-020.3647image
ENSG00000177479.18,ARIH2STADEAGMacrophages_M12.2706e-020.1702image
ENSG00000177479.18,ARIH2THCAEAGT_cells_gamma_delta1.8180e-020.2900image


Top

6. Enriched editing regions and immune gene sets for ARIH2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000177479.18,ARIH2BLCAGSVA_HALLMARK_DNA_REPAIREAG9.8327e-03-0.3940image
chr3:48977102-48978955:+BRCAGSVA_HALLMARK_UV_RESPONSE_DNEER1.5029e-02-0.4629image
ENSG00000177479.18,ARIH2BRCAGSVA_HALLMARK_ADIPOGENESISEAG5.0011e-06-0.3700image
ENSG00000177479.18,ARIH2CESCGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG1.5650e-02-0.5201image
ENSG00000177479.18,ARIH2COADGSVA_HALLMARK_P53_PATHWAYEAG1.2179e-02-0.4843image
ENSG00000177479.18,ARIH2ESCAGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG4.1528e-04-0.3723image
chr3:48923271-48925364:+ESCAGSVA_HALLMARK_ANGIOGENESISEER4.2225e-03-0.4921image
ENSG00000177479.18,ARIH2GBMGSVA_HALLMARK_ADIPOGENESISEAG5.8357e-03-0.3463image
ENSG00000177479.18,ARIH2KIRCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.3799e-03-0.5848image
ENSG00000177479.18,ARIH2KIRPGSVA_HALLMARK_ADIPOGENESISEAG4.2458e-03-0.5732image
ENSG00000177479.18,ARIH2LAMLGSVA_HALLMARK_UV_RESPONSE_DNEAG1.5973e-02-0.3207image
ENSG00000177479.18,ARIH2LGGGSVA_HALLMARK_APICAL_JUNCTIONEAG3.3321e-04-0.3866image
ENSG00000177479.18,ARIH2LUADGSVA_HALLMARK_APICAL_JUNCTIONEAG9.8523e-03-0.3132image
ENSG00000177479.18,ARIH2LUSCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG2.4405e-05-0.6814image
chr3:48936429-48936997:+OVGSVA_HALLMARK_MITOTIC_SPINDLEEER1.1164e-02-0.4723image
chr3:48977102-48978955:+OVGSVA_HALLMARK_MYC_TARGETS_V2EER4.4190e-030.5712image
ENSG00000177479.18,ARIH2OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.5515e-03-0.2929image
ENSG00000177479.18,ARIH2PRADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.2233e-02-0.3878image
ENSG00000177479.18,ARIH2SKCMGSVA_HALLMARK_HEME_METABOLISMEAG2.2089e-03-0.3703image
chr3:48977102-48978955:+STADGSVA_HALLMARK_COMPLEMENTEER1.6385e-030.4764image
chr3:48923271-48925364:+STADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER4.9203e-02-0.2264image
chr3:48936429-48936997:+STADGSVA_HALLMARK_MTORC1_SIGNALINGEER2.6234e-02-0.3652image
ENSG00000177479.18,ARIH2THCAGSVA_HALLMARK_NOTCH_SIGNALINGEAG2.3843e-02-0.2780image


Top

7. Enriched editing regions and drugs for ARIH2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000177479.18,ARIH2BRCAIPA.3EAG3.0562e-03-0.2460image
ENSG00000177479.18,ARIH2CESCDasatinibEAG3.0085e-02-0.4737image
ENSG00000177479.18,ARIH2COADDMOGEAG8.9400e-03-0.5022image
ENSG00000177479.18,ARIH2ESCAAZD.2281EAG3.1661e-02-0.2333image
chr3:48923271-48925364:+ESCAGDC.0449EER1.3174e-030.5510image
chr3:48936429-48936997:+ESCAAZ628EER1.3712e-020.4313image
ENSG00000177479.18,ARIH2GBMMG.132EAG9.4336e-030.3272image
ENSG00000177479.18,ARIH2KIRCErlotinibEAG2.3223e-030.6030image
ENSG00000177479.18,ARIH2KIRPBMS.754807EAG5.7664e-030.5570image
ENSG00000177479.18,ARIH2LAMLGemcitabineEAG3.0428e-020.2895image
ENSG00000177479.18,ARIH2LGGJNK.9LEAG6.8856e-03-0.2962image
ENSG00000177479.18,ARIH2LUADBicalutamideEAG2.2997e-030.3663image
ENSG00000177479.18,ARIH2LUSCEmbelinEAG4.6237e-04-0.5911image
chr3:48923271-48925364:+OVJNK.9LEER6.0337e-040.6605image
chr3:48936429-48936997:+OVBIRB.0796EER8.8851e-040.5927image
chr3:48977102-48978955:+OVGW.441756EER2.5601e-02-0.4644image
ENSG00000177479.18,ARIH2OVMidostaurinEAG4.8089e-030.2745image
ENSG00000177479.18,ARIH2PRADBicalutamideEAG1.7543e-020.3691image
ENSG00000177479.18,ARIH2SARCBI.D1870EAG1.7272e-020.5135image
ENSG00000177479.18,ARIH2SKCMEmbelinEAG1.9124e-040.4436image
chr3:48977102-48978955:+STADKU.55933EER1.7990e-03-0.4728image
ENSG00000177479.18,ARIH2STADAZD7762EAG2.5929e-03-0.2238image
chr3:48923271-48925364:+STADDocetaxelEER1.6459e-02-0.2744image
ENSG00000177479.18,ARIH2THCABexaroteneEAG3.6173e-030.3533image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType